首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1378137

全球神經疾病臨床試驗市場：2023-2033

Neurology Clinical Trials Market Report 2023-2033

出版日期: 2023年11月01日 | 出版商:

Visiongain Reports Ltd. | 英文 262 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2033 年，全球神經系統疾病臨床試驗市場規模將以 5.4% 的複合年增長率成長。

穿戴式裝置、行動健康應用程式和遠端監控工具的引入導致了資料收集的重大範式轉變，促進了對患者結果和疾病進展的即時監控。這些技術提供連續、公正和豐富的數據，從而提高測試結果的準確性和可靠性。此外，神經影像學的進步，包括功能性 MRI 和 PET 掃描，為了解大腦如何運作及其相互連接方式提供了無與倫比的視角。將技術融入臨床試驗過程不僅可以提高效率，還為了解神經系統疾病提供了新的機會。

該報告調查了全球神經系統疾病臨床試驗市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭狀況，我們編制了主要的概況公司。

“The Neurology Clinical Trials Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The implementation of wearable devices, mobile health applications, and remote monitoring tools has brought about a significant paradigm shift in data collection by facilitating the instantaneous monitoring of patient outcomes and the advancement of diseases. These technologies furnish an abundance of ongoing, unbiased data, thereby augmenting the accuracy and dependability of trial outcomes. In addition, developments in neuroimaging methodologies, including functional MRI and PET scans, provide unparalleled perspectives on the operation and interconnections of the brain. The incorporation of technology into the trial process not only enhances efficiency but also provides novel opportunities for comprehending neurological disorders.

What Questions Should You Ask before Buying a Market Research Report?

How is the neurology clinical trials market evolving?
What is driving and restraining the neurology clinical trials market?
How will each neurology clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
How will the market shares for each neurology clinical trials submarket develop from 2023 to 2033?
What will be the main driver for the overall market from 2023 to 2033?
Will leading neurology clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
Who are the leading players and what are their prospects over the forecast period?
What are the neurology clinical trials projects for these leading companies?
How will the industry evolve during the period between 2023 and 2033? What are the implications of

neurology clinical trials projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the neurology clinical trials market?
Where is the neurology clinical trials market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the neurology clinical trials market today, and over the next 10 years:

Our 262-page report provides 107 tables and 153 charts/graphs exclusively to you
The report highlights key lucrative areas in the industry so you can target them - NOW
It contains in-depth analysis of global, regional and national sales and growth
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the neurology clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
You will find original analyses, with business outlooks and developments
Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Study Design

Interventional
Observational
Expanded Access

Indication

Epilepsy
Stroke
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Traumatic Brain Injury (TBI)
Others

Phase

Phase I
Phase II
Phase III
Phase IV

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles and for some of the leading companies in the Neurology Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

AbbVie Inc.
Alector, Inc.
Annovis Bio
AstraZeneca
Athira Pharma, Inc.
Biogen
Charles River Laboratories
Eisai Inc
Eli Lilly and Company
ICON plc

IQVIA
Laboratory Drug Development
Medpace Holdings, Inc.
Merck & Co., Inc.
Novartis AG
Sanofi
Supernus Pharmaceuticals, Inc.
Syneos Health
Teva Pharmaceutical Industries Ltd.

Overall world revenue for Neurology Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$9,600 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Neurology Clinical Trials Market, 2023 to 2033” report help you?

In summary, our 260+ page report provides you with the following knowledge:

Revenue forecasts to 2033 for Neurology Clinical Trials Market 2023 to 2033, with forecasts for study design, indication, and phase, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the Neurology Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 19 of the major companies involved in the Neurology Clinical Trials Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Neurology Clinical Trials Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Neurology Clinical Trials Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
  - 1.7.3.1 Primary Research
  - 1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
- 3.2.1 Market Driving Factors
  - 3.2.1.1 Increasing Prevalence of Neurological Disorders
  - 3.2.1.2 Growing Adoption of Novel Technologies in Clinical Research
  - 3.2.1.3 Significant Number of CROs Providing Neurology Clinical Research Services
  - 3.2.1.4 Increasing Funding for Neurological Studies
- 3.2.2 Market Restraining Factors
  - 3.2.2.1 High Cost Associated with Neurology Clinical Studies
  - 3.2.2.2 High Failure Rate and Patient Dropout Issues
- 3.2.3 Market Opportunities
  - 3.2.3.1 Aging Population Projected to Offer Lucrative Growth Prospects
  - 3.2.3.2 Personalised Medicine and Biomarker Development in Clinical Trials
  - 3.2.3.3 Artificial Intelligence and Machine Learning in Neurology Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter's Five Forces Analysis
- 3.4.1 Supplier Power
- 3.4.2 Buyer Power
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat from Substitutes
- 3.4.5 Threat of New Entrants

4 Neurology Clinical Trials Market Analysis by Study Design

4.1 Key Findings
4.2 Study Design Segment: Market Attractiveness Index
4.3 Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
4.4 Interventional
- 4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Observational
- 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Expanded Access
- 4.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 4.6.2 Market Share by Region, 2023 & 2033 (%)

5 Neurology Clinical Trials Market Analysis by Indication

5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Neurology Clinical Trials Market Size Estimation and Forecast by Indication
5.4 Epilepsy
- 5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Stroke
- 5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Alzheimer's Disease (AD)
- 5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Parkinson's Disease (PD)
- 5.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Traumatic Brain Injury (TBI)
- 5.8.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Others
- 5.9.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 5.9.2 Market Share by Region, 2023 & 2033 (%)

6 Neurology Clinical Trials Market Analysis by Phase

6.1 Key Findings
6.2 Phase Segment: Market Attractiveness Index
6.3 Neurology Clinical Trials Market Size Estimation and Forecast by Phase
6.4 Phase I
- 6.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Phase II
- 6.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Phase III
- 6.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Phase IV
- 6.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
- 6.7.2 Market Share by Region, 2023 & 2033 (%)

7 Neurology Clinical Trials Market Analysis by Region

7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Neurology Clinical Trials Market Analysis

8.1 Key Findings
8.2 North America Neurology Clinical Trials Market Attractiveness Index
8.3 North America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Neurology Clinical Trials Market Size Estimation and Forecast by Country
8.5 North America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
8.6 North America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
8.7 North America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
8.8 U.S. Neurology Clinical Trials Market Analysis
8.9 Canada Neurology Clinical Trials Market Analysis

9 Europe Neurology Clinical Trials Market Analysis

9.1 Key Findings
9.2 Europe Neurology Clinical Trials Market Attractiveness Index
9.3 Europe Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Country
9.5 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
9.6 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Indication
9.7 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Phase
9.8 Germany Neurology Clinical Trials Market Analysis
9.9 UK Neurology Clinical Trials Market Analysis
9.10 France Neurology Clinical Trials Market Analysis
9.11 Italy Neurology Clinical Trials Market Analysis
9.12 Spain Neurology Clinical Trials Market Analysis
9.13 Rest of Europe Neurology Clinical Trials Market Analysis

10 Asia Pacific Neurology Clinical Trials Market Analysis

10.1 Key Findings
10.2 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
10.3 Asia Pacific Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Country
10.5 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
10.6 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Indication
10.7 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Phase
10.8 Japan Neurology Clinical Trials Market Analysis
10.9 China Neurology Clinical Trials Market Analysis
10.10 India Neurology Clinical Trials Market Analysis
10.11 Australia Neurology Clinical Trials Market Analysis
10.12 South Korea Neurology Clinical Trials Market Analysis
10.13 Rest of Asia Pacific Neurology Clinical Trials Market Analysis

11 Latin America Neurology Clinical Trials Market Analysis

11.1 Key Findings
11.2 Latin America Neurology Clinical Trials Market Attractiveness Index
11.3 Latin America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Country
11.5 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
11.6 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
11.7 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
11.8 Brazil Neurology Clinical Trials Market Analysis
11.9 Mexico Neurology Clinical Trials Market Analysis
11.10 Rest of Latin America Neurology Clinical Trials Market Analysis

12 MEA Neurology Clinical Trials Market Analysis

12.1 Key Findings
12.2 MEA Neurology Clinical Trials Market Attractiveness Index
12.3 MEA Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Country
12.5 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
12.6 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Indication
12.7 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Phase
12.8 GCC Neurology Clinical Trials Market Analysis
12.9 South Africa Neurology Clinical Trials Market Analysis
12.10 Rest of MEA Neurology Clinical Trials Market Analysis

13 Company Profiles

13.1 Biogen
- 13.1.1 Company Snapshot
- 13.1.2 Company Overview
- 13.1.3 Financial Analysis
  - 13.1.3.1 Net Revenue, 2015-2022
  - 13.1.3.2 R&D, 2015-2022
- 13.1.4 Product Benchmarking
- 13.1.5 Strategic Outlook
13.2 AbbVie Inc.
- 13.2.1 Company Snapshot
- 13.2.2 Company Overview
- 13.2.3 Financial Analysis
  - 13.2.3.1 Net Revenue, 2015-2022
  - 13.2.3.2 Regional Market Shares, 2022
  - 13.2.3.3 R&D, 2015-2022
- 13.2.4 Product Benchmarking
- 13.2.5 Strategic Outlook
13.3 Sanofi
- 13.3.1 Company Snapshot
- 13.3.2 Company Overview
- 13.3.3 Financial Analysis
  - 13.3.3.1 Net Revenue, 2015-2022
  - 13.3.3.2 Regional Market Shares, 2022
  - 13.3.3.3 R&D, 2015-2022
- 13.3.4 Product Benchmarking
13.4 Teva Pharmaceutical Industries Ltd.
- 13.4.1 Company Snapshot
- 13.4.2 Company Overview
- 13.4.3 Financial Analysis
  - 13.4.3.1 Net Revenue, 2015-2022
  - 13.4.3.2 Regional Market Shares, 2022
  - 13.4.3.3 R&D, 2015-2022
- 13.4.4 Product Benchmarking
13.5 Eli Lilly and Company
- 13.5.1 Company Snapshot
- 13.5.2 Company Overview
- 13.5.3 Financial Analysis
  - 13.5.3.1 Net Revenue, 2015-2022
  - 13.5.3.2 R&D, 2015-2022
- 13.5.4 Product Benchmarking
- 13.5.5 Strategic Outlook
13.6 Merck & Co., Inc.
- 13.6.1 Company Snapshot
- 13.6.2 Company Overview
- 13.6.3 Financial Analysis
  - 13.6.3.1 Net Revenue, 2015-2022
  - 13.6.3.2 Regional Market Shares, 2022
  - 13.6.3.3 R&D, 2015-2022
- 13.6.4 Product Benchmarking
13.7 Eisai Inc.
- 13.7.1 Company Snapshot
- 13.7.2 Company Overview
- 13.7.3 Financial Analysis
  - 13.7.3.1 Net Revenue, 2015-2022
  - 13.7.3.2 R&D, 2015-2022
- 13.7.4 Product Benchmarking
- 13.7.5 Strategic Outlook
13.8 AstraZeneca
- 13.8.1 Company Snapshot
- 13.8.2 Company Overview
- 13.8.3 Financial Analysis
  - 13.8.3.1 Net Revenue, 2015-2022
  - 13.8.3.2 Regional Market Shares, 2022
  - 13.8.3.3 R&D, 2015-2022
- 13.8.4 Product Benchmarking
13.9 Charles River Laboratories
- 13.9.1 Company Snapshot
- 13.9.2 Company Overview
- 13.9.3 Financial Analysis
  - 13.9.3.1 Net Revenue, 2015-2022
  - 13.9.3.2 Regional Market Shares, 2022
- 13.9.4 Product Benchmarking
13.10 Alector, Inc.
- 13.10.1 Company Snapshot
- 13.10.2 Company Overview
- 13.10.3 Product Benchmarking
- 13.10.4 Strategic Outlook
13.11 ICON plc
- 13.11.1 Company Snapshot
- 13.11.2 Company Overview
- 13.11.3 Financial Analysis
  - 13.11.3.1 Net Revenue, 2015-2022
  - 13.11.3.2 Regional Market Shares, 2022
- 13.11.4 Product Benchmarking
- 13.11.5 Strategic Outlook
13.12 IQVIA
- 13.12.1 Company Snapshot
- 13.12.2 Company Overview
- 13.12.3 Financial Analysis
  - 13.12.3.1 Net Revenue, 2015-2022
  - 13.12.3.2 Regional Market Shares, 2022
- 13.12.4 Product Benchmarking
- 13.12.5 Strategic Outlook
13.13 Labcorp Drug Development
- 13.13.1 Company Snapshot
- 13.13.2 Company Overview
- 13.13.3 Financial Analysis
  - 13.13.3.1 Net Revenue, 2015-2022
- 13.13.4 Product Benchmarking
- 13.13.5 Strategic Outlook
13.14 Medpace Holdings, Inc.
- 13.14.1 Company Snapshot
- 13.14.2 Company Overview
- 13.14.3 Financial Analysis
  - 13.14.3.1 Net Revenue, 2015-2022
- 13.14.4 Product Benchmarking
13.15 Novartis AG
- 13.15.1 Company Snapshot
- 13.15.2 Company Overview
- 13.15.3 Financial Analysis
  - 13.15.3.1 Net Revenue, 2015-2022
  - 13.15.3.2 Regional Market Shares, 2022
  - 13.15.3.3 R&D, 2015-2022
- 13.15.4 Product Benchmarking
- 13.15.5 Strategic Outlook
13.16 Syneos Health
- 13.16.1 Company Snapshot
- 13.16.2 Company Overview
- 13.16.3 Financial Analysis
  - 13.16.3.1 Net Revenue, 2015-2022
  - 13.16.3.2 Regional Market Shares, 2022
- 13.16.4 Product Benchmarking
- 13.16.5 Strategic Outlook
13.17 Annovis Bio
- 13.17.1 Company Snapshot
- 13.17.2 Company Overview
- 13.17.3 Product Benchmarking
- 13.17.4 Strategic Outlook
13.18 Supernus Pharmaceuticals, Inc.
- 13.18.1 Company Snapshot
- 13.18.2 Company Overview
- 13.18.3 Product Benchmarking
13.19 Athira Pharma, Inc.
- 13.19.1 Company Snapshot
- 13.19.2 Company Overview
- 13.19.3 Product Benchmarking

14 Conclusion and Recommendations

14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

簡介目錄圖表

List of Tables

Table 1 Neurology Clinical Trials Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
Table 2 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 3 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 4 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 5 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 6 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 Alzheimer's Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Parkinson's Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Neurology Clinical Trials Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 North America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 Europe Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 31 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Asia Pacific Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 Latin America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 MEA Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 Biogen: Product Benchmarking
Table 61 Biogen: Strategic Outlook
Table 62 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 63 AbbVie Inc.: Product Benchmarking
Table 64 AbbVie Inc.: Strategic Outlook
Table 65 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 66 Sanofi: Product Benchmarking
Table 67 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 69 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Eli Lilly and Company: Product Benchmarking
Table 71 Eli Lilly and Company: Strategic Outlook
Table 72 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Merck & Co., Inc.: Product Benchmarking
Table 74 Eisai Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Eisai Inc.: Product Benchmarking
Table 76 Eisai Inc.: Strategic Outlook
Table 77 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 AstraZeneca: Product Benchmarking
Table 79 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Charles River Laboratories: Product Benchmarking
Table 81 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Alector, Inc.: Product Benchmarking
Table 83 Alector, Inc.: Strategic Outlook
Table 84 ICON plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 ICON plc: Product Benchmarking
Table 86 ICON plc: Strategic Outlook
Table 87 IQVIA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 IQVIA: Product Benchmarking
Table 89 IQVIA: Strategic Outlook
Table 90 Labcorp Drug Development: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Labcorp Drug Development: Product Benchmarking
Table 92 Labcorp Drug Development: Strategic Outlook
Table 93 Medpace Holdings, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Medpace Holdings, Inc.: Product Benchmarking
Table 95 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Novartis AG: Product Benchmarking
Table 97 Novartis AG: Strategic Outlook
Table 98 Syneos Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Syneos Health: Product Benchmarking
Table 100 Syneos Health: Strategic Outlook
Table 101 Annovis Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Annovis Bio: Product Benchmarking
Table 103 Annovis Bio: Strategic Outlook
Table 104 Supernus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Supernus Pharmaceuticals, Inc.: Product Benchmarking
Table 106 Athira Pharma, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Athira Pharma, Inc.: Product Benchmarking

List of Figures

Figure 1 Neurology Clinical Trials Market Segmentation
Figure 2 Neurology Clinical Trials Market by Study Design: Market Attractiveness Index
Figure 3 Neurology Clinical Trials Market by Indication: Market Attractiveness Index
Figure 4 Neurology Clinical Trials Market by Phase: Market Attractiveness Index
Figure 5 Neurology Clinical Trials Market Attractiveness Index by Region
Figure 6 Neurology Clinical Trials Market: Market Dynamics
Figure 7 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
Figure 8 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
Figure 9 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
Figure 10 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
Figure 11 Neurology Clinical Trials Market: Porter's Five Forces Analysis
Figure 12 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 13 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 14 Neurology Clinical Trials Market Share Forecast by Study Design, 2023, 2028, 2033 (%)
Figure 15 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 16 Interventional Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 17 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 18 Observational Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 19 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 20 Expanded Access Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 21 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 22 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR %)
Figure 23 Neurology Clinical Trials Market Share Forecast by Indication, 2023, 2028, 2033 (%)
Figure 24 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Epilepsy Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Stroke Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Alzheimer's Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Alzheimer's Disease (AD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Parkinson's Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Parkinson's Disease (PD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Traumatic Brain Injury (TBI) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 35 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 36 Neurology Clinical Trials Market Attractiveness Index by Phase
Figure 37 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 38 Neurology Clinical Trials Market Share Forecast by Phase, 2023, 2028, 2033 (%)
Figure 39 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Phase I Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 42 Phase II Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 43 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 44 Phase III Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 45 Phase IV Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 46 Phase IV Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 47 Neurology Clinical Trials Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
Figure 48 Neurology Clinical Trials Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 49 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Mn)
Figure 50 North America Neurology Clinical Trials Market Attractiveness Index
Figure 51 North America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 52 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 53 North America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 54 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 55 North America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 56 North America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 57 North America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 58 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 59 North America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 60 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 61 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 62 Europe Neurology Clinical Trials Market Attractiveness Index
Figure 63 Europe Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 64 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 65 Europe Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 66 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 67 Europe Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 68 Europe Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 69 Europe Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 70 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 71 Europe Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 72 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 73 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 74 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 75 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
Figure 79 Asia Pacific Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 80 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 81 Asia Pacific Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 82 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 83 Asia Pacific Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 84 Asia Pacific Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 86 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 88 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 89 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 90 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 91 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 92 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 Latin America Neurology Clinical Trials Market Attractiveness Index
Figure 95 Latin America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 96 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 97 Latin America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 100 Latin America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 101 Latin America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 102 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 103 Latin America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 104 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 105 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 106 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 107 MEA Neurology Clinical Trials Market Attractiveness Index
Figure 108 MEA Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 109 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 110 MEA Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 111 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 112 MEA Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 113 MEA Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 115 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 116 MEA Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 117 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 118 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 119 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 120 Biogen: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 121 Biogen: R&D, 2015-2022 (US$ Million, AGR %)
Figure 122 AbbVie Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 123 AbbVie Inc.: Regional Market Shares (%), 2022
Figure 124 AbbVie Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 125 Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 126 Sanofi: Regional Market Shares (%), 2022
Figure 127 Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
Figure 128 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 129 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2022
Figure 130 Teva Pharmaceutical Industries Ltd.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 131 Eli Lilly and Company: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 132 Eli Lilly and Company: R&D, 2015-2022 (US$ Million, AGR %)
Figure 133 Merck & Co., Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 134 Merck & Co., Inc.: Regional Market Shares (%), 2022
Figure 135 Merck & Co., Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 136 Eisai Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 137 Eisai Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 138 AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares (%), 2022
Figure 140 AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
Figure 141 Charles River Laboratories: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 142 Charles River Laboratories: Regional Market Shares (%), 2022
Figure 143 ICON plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 144 ICON plc: Regional Market Shares (%), 2022
Figure 145 IQVIA: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 146 IQVIA: Regional Market Shares (%), 2022
Figure 147 Labcorp Drug Development: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 148 Medpace Holdings, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 149 Novartis AG: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 150 Novartis AG: Regional Market Shares (%), 2022
Figure 151 Novartis AG: R&D, 2015-2022 (US$ Million, AGR %)
Figure 152 Syneos Health: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 153 Syneos Health: Regional Market Shares (%), 2022